SCHEMBL12901467

SCHEMBL12901467

C=C1CCC(COc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
HTR3A P46098 1/20 0.41
KCNH2 Q12809 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP2 Q9UGN5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31267732 0.89 CARM1 (0.46) CARM1PRMT6TDP1DRD2DRD4
SCHEMBL1990800 0.84 TDP1 (0.57) CARM1PRMT6TDP1DRD2DRD4
SCHEMBL5525582 0.81 CARM1 (0.48) CARM1PRMT6TDP1PARP15PARP10
SCHEMBL10533845 0.80 PARP15 (0.56) CARM1PRMT6TDP1PARP15PARP10
SCHEMBL31267690 0.80 CARM1 (0.43) CARM1PRMT6TDP1DRD2DRD4
SCHEMBL2301274 0.79 CARM1 (0.49) CARM1PRMT6TDP1DRD2DRD4
SCHEMBL8356592 0.79 PARP15 (0.57) CARM1PRMT6TDP1PARP15PARP10
SCHEMBL11247511 0.77 LTA4H (0.57) CARM1PRMT6TDP1PARP15PARP10
SCHEMBL31268338 0.77 PARP15 (0.56) CARM1PRMT6TDP1PARP15PARP10
SCHEMBL8284686 0.76 PARP15 (0.50) CARM1PRMT6TDP1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688743-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2026-02-11 EP disclosed
WO-2024206153-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-10-03 WO disclosed
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2015-04-09 US disclosed
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2015-04-09 US disclosed
US-8765735-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765735-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 CARM1 2598/4885PRMT6 3345/4885TDP1 2660/4885
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 CARM1 2598/4885PRMT6 3345/4885TDP1 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.